1 December 2016 - In a rare appearance since the EpiPen controversy flared this summer, Mylan CEO Heather Bresch accepted “full responsibility” Thursday for the price hikes that caused national outrage.

“If EpiPen had to be the catalyst to show what hardworking families are facing, it will have been worth it,” she said at the Forbes Healthcare Summit in New York, referring to the upfront costs that many people encounter with high-deductible health plans. Mylan increased the price of an EpiPen two-pack nearly 550% to $608 over the past decade.

Read Stat News article